Author

Amy Funk

Frederick National Laboratory for Cancer Research

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Carleen A. Klumpp-ThomasiD· 1 shared Carolyn C. WoodroofeiD· 1 shared Craig Thomas· 1 shared Crystal G. McKnightiD· 1 shared David O. HollandiD· 1 shared Emmi Deckard· 1 shared Eric LindbergiD· 1 shared John BrognardiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Carleen A. Klumpp-ThomasORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers

Meghri Katerji, Kailey N. Jackett, Maxine R. Rubin, Eric Lindberg, Carolyn C. Woodroofe, Xiaoyi Li, Knickole Bergman, Zoe Weaver Ohler, Stephanie Jorgensen, Xiaohu Zhang, David O. Holland, Mahfuza Sharmin, Amy Funk, Katerine Nyswaner, Noelle Tesi, , John Brognard

This study identifies compound #63 as a potent LZK inhibitor that suppresses tumor growth and enhances EGFR and PI3K pathway blockade in HNSCC and ESCC.

bioRxiv · Oct 20, 2026 · PreprintCancer Biology